{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:52:34Z","timestamp":1789602754593,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002860","name":"China Sponsorship Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202006210040"],"award-info":[{"award-number":["202006210040"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.coi.2025.102687","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:43:56Z","timestamp":1761774236000},"page":"102687","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Local complement inhibition by selective precision-targeted therapies"],"prefix":"10.1016","volume":"98","author":[{"given":"Haiyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan J","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balthasar A","family":"Heesters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul WHI","family":"Parren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5186-2290","authenticated-orcid":false,"given":"Leendert A","family":"Trouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102687_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00441-010-1034-0","article-title":"The complement system","volume":"343","author":"Sarma","year":"2011","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.coi.2025.102687_bib2","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2024.101922","article-title":"Enhancing complement activation by therapeutic anti-tumor antibodies: mechanisms, strategies, and engineering approaches","volume":"77","author":"Ovcinnikovs","year":"2025","journal-title":"Semin Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.it.2008.11.003","article-title":"Complement activation and inhibition: a delicate balance","volume":"30","author":"Sj\u00f6berg","year":"2009","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrrheum.2017.125","article-title":"The complement system as a potential therapeutic target in rheumatic disease","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2025.102687_bib6","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.coi.2025.102687_bib7","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.molimm.2019.06.002","article-title":"The role of complement in antibody mediated transplant rejection","volume":"112","author":"Thurman","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib8","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00281-021-00892-7","article-title":"Tipping the balance: intricate roles of the complement system in disease and therapy","volume":"43","author":"Pouw","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.coi.2025.102687_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2025.107002","article-title":"Autoantibodies and therapeutic antibodies against complement factor H","volume":"274","author":"Nugteren","year":"2025","journal-title":"Immunol Lett"},{"key":"10.1016\/j.coi.2025.102687_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01851","article-title":"Be on target: strategies of targeting alternative and lectin pathway components in complement-mediated diseases","volume":"9","author":"Dobo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.molimm.2019.07.030","article-title":"Compendium of current complement therapeutics","volume":"114","author":"Zelek","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib12","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1111\/ajt.14426","article-title":"High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine","volume":"17","author":"McNamara","year":"2017","journal-title":"Am J Transpl"},{"key":"10.1016\/j.coi.2025.102687_bib13","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2217\/imt-2022-0085","article-title":"Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?","volume":"14","author":"Berentsen","year":"2022","journal-title":"Immunotherapy"},{"key":"10.1016\/j.coi.2025.102687_bib14","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3201\/eid3103.241182","article-title":"Meningococcal sepsis in patient with paroxysmal nocturnal hemoglobinuria during pegcetacoplan therapy","volume":"31","author":"Starck","year":"2025","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.coi.2025.102687_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/imm.13083","article-title":"Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species","volume":"157","author":"Zelek","year":"2019","journal-title":"Immunology"},{"key":"10.1016\/j.coi.2025.102687_bib16","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00277-022-04903-x","article-title":"Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria","volume":"101","author":"Wong","year":"2022","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coi.2025.102687_bib17","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.jaci.2020.08.028","article-title":"ARGX-117, a therapeutic complement inhibiting antibody targeting C2","volume":"147","author":"Van de Walle","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib18","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jaci.2009.07.017","article-title":"Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks","volume":"124","author":"Craig","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib19","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1007\/s00467-024-06284-x","article-title":"Anti-factor B antibodies in atypical hemolytic uremic syndrome","volume":"39","author":"Khandelwal","year":"2024","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.coi.2025.102687_bib20","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/S0041-1345(99)00297-3","article-title":"The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system","volume":"31","author":"Tanhehco","year":"1999","journal-title":"Transpl Proc"},{"key":"10.1016\/j.coi.2025.102687_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350816","article-title":"Complement-targeted therapeutics: are we there yet, or just getting started?","volume":"54","author":"Ricklin","year":"2024","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib22","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM199010253231707","article-title":"Inherited complete deficiency of 20-kiloDalton homologous restriction factor-(Cd59) as a cause of paroxysmal-nocturnal hemoglobinuria","volume":"323","author":"Yamashina","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102687_bib23","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00277-007-0420-5","article-title":"Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome","volume":"87","author":"Kaiafa","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.coi.2025.102687_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2023.04.010","article-title":"The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment (vol 100, pg 225, 2021)","volume":"104","author":"Ariceta","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.coi.2025.102687_bib25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s10198-022-01556-5","article-title":"Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands","volume":"24","author":"Quist","year":"2023","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.coi.2025.102687_sbref26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2169\/internalmedicine.1893-23","article-title":"Serious bacterial infections associated with eculizumab: a pharmacovigilance study","volume":"63","author":"Okusa","year":"2024","journal-title":"Intern Med"},{"key":"10.1016\/j.coi.2025.102687_sbref27","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1093\/jimmun\/vkaf053","article-title":"Tissue-targeted regulators of complement for amelioration of human disease: rationale and novel therapeutic strategies","volume":"214","author":"Liu","year":"2025","journal-title":"J Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib28","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF02231555","article-title":"Complement split product C3d as an indicator of disease-activity in systemic lupus-erythematosus","volume":"12","author":"Rother","year":"1993","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coi.2025.102687_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02237","article-title":"Interpretation of serological complement biomarkers in disease","volume":"9","author":"Ekdahl","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib30","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.1182\/blood-2011-06-359646","article-title":"Design and development of TT30, a novel C3d-targeted C3\/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases","volume":"118","author":"Fridkis-Hareli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102687_bib31","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1167\/iovs.08-2222","article-title":"A targeted inhibitor of the alternative complement pathway reduces angiogenesis in a mouse model of age-related macular degeneration","volume":"50","author":"Rohrer","year":"2009","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"10.1016\/j.coi.2025.102687_bib32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V126.23.2137.2137","article-title":"Safety and pharmacokinetics of the complement inhibitor TT30 in a phase I trial for untreated PNH patients","volume":"126","author":"Risitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102687_bib33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molimm.2018.09.013","article-title":"The human complement receptor type 2 (CR2)\/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models","volume":"105","author":"Fridkis-Hareli","year":"2019","journal-title":"Mol Immunol"},{"key":"10.1016\/j.coi.2025.102687_sbref34","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ymthe.2024.02.001","article-title":"C3d-Targeted factor H inhibits tissue complement in disease models and reduces glomerular injury without affecting circulating complement","volume":"32","author":"Liu","year":"2024","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2025.102687_sbref35","doi-asserted-by":"crossref","first-page":"10S","DOI":"10.1681\/ASN.20245njhsrst","article-title":"ADX-097, a tissue-targeted complement inhibitor for the treatment of kidney diseases: phase 1 results in healthy participants and model-informed phase 2 dose selection","volume":"35","author":"Jilma","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.coi.2025.102687_sbref36","doi-asserted-by":"crossref","DOI":"10.1093\/immhor\/vlae006","article-title":"Improved therapeutic efficacy of a bifunctional anti-C5 mAb-FH SCR1-5 fusion protein over anti-C5 mAb in an accelerated mouse model of C3 glomerulopathy","volume":"9","author":"Sato","year":"2025","journal-title":"Immunohorizons"},{"key":"10.1016\/j.coi.2025.102687_sbref37","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1182\/blood-2024-210086","article-title":"KP104, a bifunctional C5 mab-factor H fusion protein, demonstrates sustained long-term efficacy and safety in complement inhibitor-naive PNH patients: updated results from a phase 2 study at 36\/38 weeks of Obd treatment","volume":"144","author":"Zhang","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.coi.2025.102687_bib38","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao6459","article-title":"Targeted complement inhibition salvages stressed neurons and inhibits neuroinflammation after stroke in mice","volume":"10","author":"Alawieh","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2025.102687_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0464-8","article-title":"Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement","volume":"12","author":"Alawieh","year":"2015","journal-title":"J Neuroinflamm"},{"key":"10.1016\/j.coi.2025.102687_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575154","article-title":"C2 IgM natural antibody enhances inflammation and its use in the recombinant single chain antibody-fused complement inhibitor C2-Crry to target therapeutics to joints attenuates arthritis in mice","volume":"11","author":"Banda","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102687_sbref41","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4254\/wjh.v16.i10.1188","article-title":"Complement activation targeted inhibitor C2-FH ameliorates acetaminophen-induced liver injury in mice","volume":"16","author":"Li","year":"2024","journal-title":"World J Hepatol"},{"key":"10.1016\/j.coi.2025.102687_sbref42","article-title":"Targeted complement inhibition using bispecific antibodies that bind local antigens and endogenous complement regulators","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102687_bib43","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.ard.2025.06.2130","article-title":"Development of bispecific antibodies that drive selective targeted local complement inhibition on rheumatoid arthritis-related antigens","author":"Wang","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102687_bib44","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/bloodadvances.2024013587","article-title":"Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro","volume":"9","author":"ter Avest","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.coi.2025.102687_sbref45","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1182\/blood-2019-127005","article-title":"Prophylactic antibiotic use and risk of meningococcal infections in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) treated with eculizumab who received meningococcal vaccination: results from the International PNH Registry","volume":"134","author":"Patriquin","year":"2019","journal-title":"Blood"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525001633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:00:55Z","timestamp":1780635655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525001633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"alternative-id":["S0952791525001633"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102687","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local complement inhibition by selective precision-targeted therapies","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102687","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102687"}}